United States: FDA Proposes Policy Change Concerning 5-Year NCE Exclusivity for Certain Fixed-Combination Drugs

Prompted by citizen petitions filed by Ropes & Gray and by two other companies, FDA issued draft guidance proposed a change in the Agency's interpretation of 5-year new chemical entity ("NCE") exclusivity as applied to certain fixed-combination drug products ("fixed-combinations"). Fixed-combinations are drug products that generally include two or more drug substances (i.e., active ingredients) in a fixed ratio, synthetically combined in a single dosage form. Historically, FDA interpreted the relevant statutory and regulatory provisions to preclude 5-year NCE exclusivity for a fixed-combination that included both a new active moiety a previously approved active moiety. Under FDA's new interpretation, such a fixed-combination will be eligible for 5-year NCE exclusivity so long as it contains at least one drug substance, no active moiety of which has been previously approved.

Historical Approach

FDA's long-standing position has been that fixed-combinations are eligible for 5-year NCE exclusivity only if every active moiety in the combination is new – if just one of the active moieties has been approved previously, the fixed-combination is not eligible for 5-year NCE exclusivity. This approach was based on FDA's interpretation of the 5-year NCE exclusivity provision, which states:

If an application submitted under subsection (b) of this section for a drug, no active ingredient (including any ester or salt of the active ingredient) of which has been approved in any other application under subsection (b) of this section, is approved . . . no application may be submitted under this subsection which refers to the drug for which the subsection (b) application was submitted before the expiration of five years from the date of approval of the application under subsection (b) of this section...[1]

The statute thus includes clauses describing both eligibility for 5-year NCE exclusivity (the "eligibility clause") and the parameters of this exclusivity once it attaches (the "bar clause"). Historically, FDA interpreted the term "drug" in the eligibility clause to mean "drug product," while it interpreted the term "drug" in the bar clause to mean "drug substance." Because FDA interpreted "drug" to mean "drug product" in the eligibility clause, a drug product could only be eligible for 5-year NCE exclusivity if "no active ingredient" in the drug product had previously been approved. This led to FDA's conclusion that fixed-combinations including both a new active ingredient and a previously approved active ingredient were not eligible for 5-year NCE exclusivity.

Citizen Petitions

In 2013, three companies each petitioned FDA to revise its interpretation of 5-year NCE exclusivity with respect to certain fixed-combinations. The petitioners argued that FDA's interpretation of the word "drug" to mean two different things in the 5-year NCE exclusivity provision was contrary to the statutory language, Congressional intent, and FDA's own implementing regulations. In addition, the petitioners argued that FDA's historical approach leads to illogical and arbitrary results by putting undue weight on the order in which a sponsor's applications are approved in determining their eligibility for 5-year NCE exclusivity.[2] The petitioners also pointed out that FDA's policy favors the development of a new active ingredient in a single-entity drug product that is cross-labeled for use with another drug product that contains a previously approved active ingredient, as opposed to development of the new active ingredient in a fixed-combination.

Response to Petitions and New Interpretation

In its consolidated response to the three petitions, FDA concluded that the petitioners articulated a reasonable alternative interpretation of the statute and regulations that would be beneficial to the public health. FDA recognized that a change in policy was warranted given recent changes in the field of fixed-combinations. FDA also acknowledged that its historical approach to fixed-combinations could result in suboptimal development strategies.

Accordingly, FDA announced that it is proposing to change its interpretation of 5-year NCE exclusivity to align the exclusivity incentives more closely with FDA's public health goals. Under this interpretation, the term "drug" in the eligibility clause (and in the regulatory definition of "new chemical entity") will refer to "drug substance," not "drug product." If FDA adopts this interpretation, a 5-year NCE exclusivity determination will be made for each drug substance in a drug product, not for the drug product as a whole. As a result, a fixed-combination drug product that contains a drug substance with a single, new active moiety would be eligible for 5-year NCE exclusivity, even if the fixed-combination also contains a drug substance with a previously approved active moiety.

New Draft Guidance

On the same day that FDA responded to the petitions, it issued new draft guidance proposing and seeking public comment on the new interpretation that would recognize 5-year NCE exclusivity for certain fixed-combinations. FDA stated that if, at the conclusion of the comment period, it is convinced that the proposed new interpretation is appropriate, it will issue final guidance and will adopt the new interpretation. The draft guidance also states that the new interpretation will not apply to fixed-combinations that are approved "prior to adopting the new interpretation."

FDA will be accepting comments on the draft guidance until April 25, 2014. 

If you would like to discuss the foregoing or any related matter, please contact any member of Ropes & Gray's FDA regulatory practice or your usual Ropes & Gray advisor. 

[1] 21 U.S.C. § 355(j)(f)(F)(ii); see also 21 U.S.C. § 355(c)(3)(E)(ii).

[2] Under FDA's historical interpretation, if a single-entity drug product containing a new active ingredient was approved before a fixed-combination containing the same active ingredient together with a previously approved active ingredient, both the single-entity product and the fixed-combination product could benefit from the single-entity product's 5-year NCE exclusivity. If the order of approval of these applications were to be reversed, however, neither the fixed combination nor the single-entity drug product would be eligible for 5-year NCE exclusivity.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions